Precision BioSciences (DTIL) said Monday its investigational new drug application for PBGENE-HBV in vivo gene editing program has received the US Food and Drug Administration's clearance to treat chronic hepatitis B.
The company is in final stages of US site activation to start enrolling participants in its Eliminate-B study in the country and will soon initiate phase 1 clinical activities at the Liver Center at Massachusetts General Hospital, Precision added.
The trial is already enrolling patients in Moldova, Hong Kong, and New Zealand, the company said, adding that it intends to expand the trial in the UK.
Shares of the company were up more than 7% in recent Monday premarket activity.
Price: 5.40, Change: +0.36, Percent Change: +7.14
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。